medical research foundation
medical research foundation Company Information
Company Number
07366816
Registered Address
99 charterhouse street, london, EC1M 6HR
Industry
Other business support service activities n.e.c.
Telephone
02072508200
Next Accounts Due
December 2024
Group Structure
View All
Shareholders
-0%
medical research foundation Estimated Valuation
Pomanda estimates the enterprise value of MEDICAL RESEARCH FOUNDATION at £3.1m based on a Turnover of £5.1m and 0.61x industry multiple (adjusted for size and gross margin).
medical research foundation Estimated Valuation
Pomanda estimates the enterprise value of MEDICAL RESEARCH FOUNDATION at £0 based on an EBITDA of £-3.4m and a 4.63x industry multiple (adjusted for size and gross margin).
medical research foundation Estimated Valuation
Pomanda estimates the enterprise value of MEDICAL RESEARCH FOUNDATION at £153.7m based on Net Assets of £66.4m and 2.31x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Medical Research Foundation AI Business Plan
In just minutes, we combine Pomanda’s company and industry data with cutting edge Artificial Intelligence to build a comprehensive 27 section business plan. You then have 60 days to tailor the information, decide which sections to include or exclude, and add your own branding logos, images and color scheme to create your perfect plan.
Medical Research Foundation Overview
Medical Research Foundation is a live company located in london, EC1M 6HR with a Companies House number of 07366816. It operates in the other business support service activities n.e.c. sector, SIC Code 82990. Founded in September 2010, it's largest shareholder is unknown. Medical Research Foundation is a established, mid sized company, Pomanda has estimated its turnover at £5.1m with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Medical Research Foundation Health Check
Pomanda's financial health check has awarded Medical Research Foundation a 3.5 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 4 areas for improvement. Company Health Check FAQs
4 Strong
1 Regular
4 Weak
Size
annual sales of £5.1m, make it larger than the average company (£3m)
£5.1m - Medical Research Foundation
£3m - Industry AVG
Growth
3 year (CAGR) sales growth of -18%, show it is growing at a slower rate (4%)
-18% - Medical Research Foundation
4% - Industry AVG
Production
with a gross margin of 38.9%, this company has a comparable cost of product (38.9%)
38.9% - Medical Research Foundation
38.9% - Industry AVG
Profitability
an operating margin of -71.2% make it less profitable than the average company (6.5%)
-71.2% - Medical Research Foundation
6.5% - Industry AVG
Employees
with 30 employees, this is above the industry average (20)
30 - Medical Research Foundation
20 - Industry AVG
Pay Structure
on an average salary of £55.6k, the company has a higher pay structure (£43.7k)
£55.6k - Medical Research Foundation
£43.7k - Industry AVG
Efficiency
resulting in sales per employee of £168.5k, this is more efficient (£136.7k)
£168.5k - Medical Research Foundation
£136.7k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Medical Research Foundation
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Medical Research Foundation
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Medical Research Foundation
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 14 weeks, this is less cash available to meet short term requirements (28 weeks)
14 weeks - Medical Research Foundation
28 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 19.9%, this is a lower level of debt than the average (60%)
19.9% - Medical Research Foundation
60% - Industry AVG
medical research foundation Credit Report and Business Information
Medical Research Foundation Competitor Analysis
Perform a competitor analysis for medical research foundation by selecting its closest rivals and benchmarking them against 12 key performance metrics.
medical research foundation Ownership
MEDICAL RESEARCH FOUNDATION group structure
Medical Research Foundation has no subsidiary companies.
Ultimate parent company
MEDICAL RESEARCH FOUNDATION
07366816
medical research foundation directors
Medical Research Foundation currently has 10 directors. The longest serving directors include Mrs Susan Wilkinson (Jun 2016) and Professor Patricia Kingori (Apr 2021).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mrs Susan Wilkinson | 67 years | Jun 2016 | - | Director | |
| Professor Patricia Kingori | United Kingdom | 46 years | Apr 2021 | - | Director |
| Ms Kristen Gallagher | United Kingdom | 52 years | Jun 2021 | - | Director |
| Mr Jonathan Beck | United Kingdom | 56 years | Apr 2022 | - | Director |
| Professor Richard Coward | United Kingdom | 56 years | Apr 2022 | - | Director |
| Professor Rosalind Smyth | United Kingdom | 65 years | Apr 2022 | - | Director |
| Mr Richard Walters | England | 39 years | Jul 2022 | - | Director |
| Professor Moira Whyte | United Kingdom | 64 years | Apr 2023 | - | Director |
| Professor Paul Moss | United Kingdom | 63 years | May 2023 | - | Director |
| Professor Melanie Newport | United Kingdom | 61 years | Apr 2024 | - | Director |
MEDICAL RESEARCH FOUNDATION financials
Medical Research Foundation's latest turnover from March 2023 is £5.1 million and the company has net assets of £66.4 million. According to their latest financial statements, Medical Research Foundation has 30 employees and maintains cash reserves of £2.9 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 5,056,000 | 5,709,000 | 3,307,000 | 9,226,000 | 3,657,000 | 4,321,000 | 9,040,000 | -1,357,000 | 7,745,000 | 5,664,000 | 2,589,000 | 2,854,000 | |
| Other Income Or Grants | |||||||||||||
| Cost Of Sales | |||||||||||||
| Gross Profit | |||||||||||||
| Admin Expenses | |||||||||||||
| Operating Profit | |||||||||||||
| Interest Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Pre-Tax Profit | -3,464,000 | 2,184,000 | 12,079,000 | 302,000 | -2,381,000 | -869,000 | 8,804,000 | -1,518,000 | 7,599,000 | 1,549,000 | -679,000 | -448,000 | |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Profit After Tax | -3,464,000 | 2,184,000 | 12,079,000 | 302,000 | -2,381,000 | -869,000 | 8,804,000 | -1,518,000 | 7,599,000 | 1,549,000 | -679,000 | -448,000 | |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Retained Profit | -3,464,000 | 2,184,000 | 12,079,000 | 302,000 | -2,381,000 | -869,000 | 8,804,000 | -1,518,000 | 7,599,000 | 1,549,000 | -679,000 | -448,000 | |
| Employee Costs | 1,669,000 | 1,668,000 | 1,366,000 | 1,096,000 | 623,000 | 119,000 | 0 | ||||||
| Number Of Employees | 30 | 31 | 23 | 19 | 11 | 7 | |||||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 7,642,000 | 7,829,000 | 7,921,000 | 8,066,000 | 8,206,000 | 8,320,000 | 8,545,000 | 8,781,000 | 7,243,000 | 5,580,000 | 5,890,000 | 6,304,000 | 0 |
| Intangible Assets | 25,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 55,443,000 | 55,278,000 | 60,345,000 | 51,509,000 | 55,609,000 | 51,669,000 | 50,906,000 | 44,462,000 | 48,291,000 | 42,043,000 | 39,270,000 | 35,109,000 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 63,110,000 | 63,107,000 | 68,266,000 | 59,575,000 | 63,815,000 | 59,989,000 | 59,451,000 | 53,243,000 | 55,534,000 | 47,623,000 | 45,160,000 | 41,413,000 | 0 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 6,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 1,599,000 | 1,330,000 | 542,000 | 617,000 | 1,000,000 | 927,000 | 412,000 | 221,000 | 163,000 | 6,000 | 18,000 | 325,000 | 0 |
| Cash | 2,874,000 | 3,612,000 | 3,754,000 | 3,796,000 | 2,992,000 | 2,754,000 | 3,725,000 | 2,130,000 | 2,699,000 | 7,680,000 | 5,311,000 | 4,563,000 | 0 |
| misc current assets | 15,344,000 | 21,083,000 | 11,163,000 | 7,655,000 | 3,132,000 | 5,109,000 | 6,303,000 | 6,023,000 | 6,500,000 | 0 | 111,000 | 0 | 0 |
| total current assets | 19,817,000 | 26,025,000 | 15,459,000 | 12,068,000 | 7,124,000 | 8,790,000 | 10,446,000 | 8,374,000 | 9,362,000 | 7,686,000 | 5,440,000 | 4,888,000 | 0 |
| total assets | 82,927,000 | 89,132,000 | 83,725,000 | 71,643,000 | 70,939,000 | 68,779,000 | 69,897,000 | 61,617,000 | 64,896,000 | 55,309,000 | 50,600,000 | 46,301,000 | 0 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 36,000 | 1,000 | 21,000 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 10,617,000 | 11,147,000 | 9,314,000 | 7,770,000 | 6,737,000 | 3,258,000 | 3,700,000 | 6,628,000 | 5,597,000 | 5,436,000 | 4,707,000 | 2,500,000 | 0 |
| total current liabilities | 10,617,000 | 11,147,000 | 9,314,000 | 7,770,000 | 6,737,000 | 3,258,000 | 3,700,000 | 6,628,000 | 5,633,000 | 5,437,000 | 4,728,000 | 2,500,000 | 0 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 24,000 | 40,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 5,843,000 | 4,538,000 | 3,188,000 | 4,729,000 | 5,360,000 | 8,221,000 | 8,797,000 | 4,155,000 | 3,163,000 | 3,091,000 | 2,273,000 | 3,235,000 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 5,867,000 | 4,578,000 | 3,188,000 | 4,729,000 | 5,360,000 | 8,221,000 | 8,797,000 | 4,155,000 | 3,163,000 | 3,091,000 | 2,273,000 | 3,235,000 | 0 |
| total liabilities | 16,484,000 | 15,725,000 | 12,502,000 | 12,499,000 | 12,097,000 | 11,479,000 | 12,497,000 | 10,783,000 | 8,796,000 | 8,528,000 | 7,001,000 | 5,735,000 | 0 |
| net assets | 66,443,000 | 73,407,000 | 71,223,000 | 59,144,000 | 58,842,000 | 57,300,000 | 57,400,000 | 50,834,000 | 56,100,000 | 46,781,000 | 43,599,000 | 40,566,000 | 0 |
| total shareholders funds | 66,443,000 | 73,407,000 | 71,223,000 | 59,144,000 | 58,842,000 | 57,300,000 | 57,400,000 | 50,834,000 | 56,100,000 | 46,781,000 | 43,599,000 | 40,566,000 | 0 |
| Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||
| Operating Profit | |||||||||||||
| Depreciation | 147,000 | 151,000 | 145,000 | 145,000 | 145,000 | 235,000 | 236,000 | 161,000 | 146,000 | 310,000 | 316,000 | 6,000 | |
| Amortisation | 6,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 269,000 | 788,000 | -75,000 | -383,000 | 73,000 | 509,000 | 197,000 | 58,000 | 157,000 | -12,000 | -307,000 | 325,000 | 0 |
| Creditors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -36,000 | 35,000 | -20,000 | 21,000 | 0 | 0 |
| Accruals and Deferred Income | -546,000 | 1,873,000 | 1,544,000 | 1,033,000 | 3,479,000 | -442,000 | -2,928,000 | 1,031,000 | 161,000 | 729,000 | 2,207,000 | 2,500,000 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | |||||||||||||
| Investing Activities | |||||||||||||
| capital expenditure | 0 | 0 | 0 | 0 | -48,000 | 1,199,000 | -20,000 | -621,000 | -10,966,000 | ||||
| Change in Investments | 165,000 | -5,067,000 | 8,836,000 | -4,100,000 | 3,940,000 | 763,000 | 6,444,000 | -3,829,000 | 6,248,000 | 2,773,000 | 4,161,000 | 35,109,000 | 0 |
| cash flow from investments | -165,000 | 5,067,000 | -8,836,000 | 4,100,000 | -3,988,000 | 436,000 | -6,464,000 | 3,208,000 | -17,214,000 | ||||
| Financing Activities | |||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 1,305,000 | 1,350,000 | -1,541,000 | -631,000 | -2,861,000 | -576,000 | 4,642,000 | 992,000 | 72,000 | 818,000 | -962,000 | 3,235,000 | 0 |
| share issue | |||||||||||||
| interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| cash flow from financing | -2,195,000 | 1,350,000 | -1,541,000 | -631,000 | 1,062,000 | 193,000 | 2,404,000 | -2,756,000 | 1,792,000 | 2,451,000 | 2,750,000 | 44,249,000 | |
| cash and cash equivalents | |||||||||||||
| cash | -738,000 | -142,000 | -42,000 | 804,000 | 238,000 | -971,000 | 1,595,000 | -569,000 | -4,981,000 | 2,369,000 | 748,000 | 4,563,000 | 0 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | -738,000 | -142,000 | -42,000 | 804,000 | 238,000 | -971,000 | 1,595,000 | -569,000 | -4,981,000 | 2,369,000 | 748,000 | 4,563,000 | 0 |
P&L
March 2023turnover
5.1m
-11%
operating profit
-3.6m
0%
gross margin
38.9%
+1.48%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2023net assets
66.4m
-0.09%
total assets
82.9m
-0.07%
cash
2.9m
-0.2%
net assets
Total assets minus all liabilities
Similar Companies
medical research foundation company details
company number
07366816
Type
Private Limited by guarantee without Share Capital Exempt from using Limited
industry
82990 - Other business support service activities n.e.c.
incorporation date
September 2010
age
14
accounts
Full Accounts
ultimate parent company
previous names
N/A
incorporated
UK
address
99 charterhouse street, london, EC1M 6HR
last accounts submitted
March 2023
medical research foundation Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to medical research foundation.
medical research foundation Companies House Filings - See Documents
| date | description | view/download |
|---|
